- Home
- NCA vs PRQR Comparison
NCA vs PRQR Comparison
Compare NCA & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCA
- PRQR
- Stock Information
- Founded
- NCA 1987
- PRQR 2012
- Country
- NCA United States
- PRQR Netherlands
- Employees
- NCA N/A
- PRQR N/A
- Industry
- NCA Investment Managers
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- NCA Finance
- PRQR Health Care
- Exchange
- NCA Nasdaq
- PRQR Nasdaq
- Market Cap
- NCA 280.8M
- PRQR 232.8M
- IPO Year
- NCA N/A
- PRQR 2014
- Fundamental
- Price
- NCA $8.71
- PRQR $2.04
- Analyst Decision
- NCA
- PRQR Strong Buy
- Analyst Count
- NCA 0
- PRQR 8
- Target Price
- NCA N/A
- PRQR $8.88
- AVG Volume (30 Days)
- NCA 59.6K
- PRQR 367.9K
- Earning Date
- NCA 01-01-0001
- PRQR 11-06-2025
- Dividend Yield
- NCA 3.92%
- PRQR N/A
- EPS Growth
- NCA N/A
- PRQR N/A
- EPS
- NCA N/A
- PRQR N/A
- Revenue
- NCA N/A
- PRQR $20,129,184.00
- Revenue This Year
- NCA N/A
- PRQR N/A
- Revenue Next Year
- NCA N/A
- PRQR N/A
- P/E Ratio
- NCA N/A
- PRQR N/A
- Revenue Growth
- NCA N/A
- PRQR 8.65
- 52 Week Low
- NCA $7.77
- PRQR $1.07
- 52 Week High
- NCA $9.12
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- NCA 69.15
- PRQR 39.56
- Support Level
- NCA $8.51
- PRQR $1.91
- Resistance Level
- NCA $8.54
- PRQR $2.50
- Average True Range (ATR)
- NCA 0.06
- PRQR 0.15
- MACD
- NCA 0.02
- PRQR -0.04
- Stochastic Oscillator
- NCA 98.93
- PRQR 17.80
About NCA Nuveen California Municipal Value Fund
Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. Its primary objective is to provide current income exempt from regular federal and California income taxes. The fund's secondary objective is to enhance portfolio value relative to the California municipal bond market by investing in tax-exempt California municipal securities that the Fund's investment adviser and/or the Fund's sub-adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.